Related Experiment Videos
Longitudinal multimodal evoked potential studies in abetalipoproteinaemia
1Division of Neurology, Hospital for Sick Children, University of Toronto, Ontario, Canada.
Summary
High-dose vitamin E therapy may stabilize neurological symptoms in abetalipoproteinaemia patients. Serial neurophysiological assessments, particularly sensory evoked potentials (SEP), are crucial for monitoring disease progression in this rare genetic disorder.
Area of Science:
- Neurology
- Clinical Medicine
- Genetics
Background:
- Abetalipoproteinaemia is a rare genetic disorder characterized by fat malabsorption and progressive neurological dysfunction.
- High-dose vitamin E therapy has shown potential in managing the neurological manifestations of abetalipoproteinaemia.
Purpose of the Study:
- To evaluate the long-term effects of high-dose vitamin E therapy on neurological status in abetalipoproteinaemia patients.
- To assess the utility of neurophysiological tests in monitoring disease progression and treatment response.
Main Methods:
- Longitudinal follow-up of five abetalipoproteinaemia patients initiated on high-dose vitamin E therapy since 1982.
- Serial neurophysiological assessments including Auditory Brainstem Responses (ABR), Visual Evoked Potentials (VEP), and Sensory Evoked Potentials (SEP) every 6-12 months.
- Correlation of neurophysiological findings with neurological status and vitamin E levels.
Main Results:
- Neurological status remained relatively stable in most patients over a four-year period.
- Auditory Brainstem Responses (ABR) were consistently normal.
- Visual Evoked Potentials (VEP) showed improvement in one patient and stability in others.
- Cortical Sensory Evoked Potentials (SEP) were abnormal in most patients and fluctuated with neurological deterioration.
Conclusions:
- Serial neurological and neurophysiological assessments are vital for abetalipoproteinaemia patient follow-up.
- Sensory Evoked Potentials (SEP) appear to be the most sensitive neurophysiological measure for detecting neurological changes in abetalipoproteinaemia.